Perspective Therapeutics

FactSet Survey Analysts Give Perspective Therapeutics a Buy Rating

Perspective Therapeutics has an average rating of buy and mean price target of $13.38, according to analysts polled by FactSet.

RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk

Truist Securities maintains its rating on Perspective Therapeutics, adjusting it from Buy to Buy, with a target price revised from $10.00 to $8.00. Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company focused on the treatment of systemic cancer, with proprietary technology utilizing the alpha-emitting isotope 212Pb

Truist Securities: Maintains Perspective Therapeutics Rating

Millennium Management LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during Q4, purchasing 1,295,343 shares valued at approximately $4.13 million. Other hedge funds also increased their holdings in the company. Perspective Therapeutics' stock rose 4.7% to $2.70, with analysts giving it an average rating of "Buy" and a consensus target price of $12.50. Insider transactions included CEO Johan M. Spoor and Director Robert F. Williamson III buying shares, increasing their ownership significantly. The company focuses on developing precision-targeted alpha therapies for oncology.

Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Velan Capital Investment Management LP has acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX), purchasing 500,000 shares valued at approximately $1.6 million. This investment represents 1.4% of Velan's holdings, making CATX its 14th largest position. Other institutional investors have also increased their stakes in CATX. Insider transactions include CFO Juan Graham and CEO Johan M. Spoor purchasing shares, indicating confidence in the company. Analysts have given CATX a consensus rating of "Buy" with an average price target of $12.50, while the stock currently trades at $2.63.

FactSet Survey Analysts Give Perspective Therapeutics a Buy Rating

Summary

Impact Analysis